Literature DB >> 20143101

[Quality of life and alexithymia in somatoform pain disorder].

D Garcia Nuñez1, M Rufer, K Leenen, K-L Majohr, H Grabe, J Jenewein.   

Abstract

BACKGROUND: Patients with somatoform pain disorders (SPD) frequently display reduced quality of life (QoL) and increased levels of alexithymia. This study investigated the association of QoL and alexithymia in a sample of SPD. PATIENTS AND METHODS: Fifty-one patients with SPD (average time since onset: 11.6 years) were assessed in terms of alexithymia (TAS-20), QoL (WHOQOL-BREF), psychological distress and somatisation (SCL-90-R), and depression (MADRS).
RESULTS: In SPD patients a significant negative correlation was observed between QoL and alexithymia, particularly the psychological domain of QoL and the TAS-20 total score (r=-.63, p<.001). The TAS-20 subscale "Difficulty Describing Feelings" was revealed to be a significant predictor of the psychological domain of QoL (beta=-.34, p<.01), even after controlling for depression, somatisation and gender.
CONCLUSION: Patients with SPD show a remarkably reduced QoL and alexithymia appears to play a significant role for low QoL. Clinicians need to pay careful attention to alexithymia with regard to diagnosis and treatment planning in SPD patients.

Entities:  

Mesh:

Year:  2010        PMID: 20143101     DOI: 10.1007/s00482-009-0882-6

Source DB:  PubMed          Journal:  Schmerz        ISSN: 0932-433X            Impact factor:   1.107


  23 in total

1.  [Factoral structure and psychometric properties of the German version of the Toronto Alexithymia Scale (TAS-20) in psychosomatic patients].

Authors:  M Franz; C Schneider; R Schäfer; N Schmitz; K Zweyer
Journal:  Psychother Psychosom Med Psychol       Date:  2001-02

2.  Somatoform disorders as disorders of affect regulation: a study comparing the TAS-20 with non-self-report measures of alexithymia.

Authors:  Elisabeth Waller; Carl Eduard Scheidt
Journal:  J Psychosom Res       Date:  2004-09       Impact factor: 3.006

Review 3.  DSM-IV pain disorder in the general population. An exploration of the structure and threshold of medically unexplained pain symptoms.

Authors:  Christine Fröhlich; Frank Jacobi; Hans-Ulrich Wittchen
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2005-11-18       Impact factor: 5.270

4.  A comparison of chronic pain patients and controls on traumatic events in childhood.

Authors:  R T Goldberg; R Goldstein
Journal:  Disabil Rehabil       Date:  2000-11-20       Impact factor: 3.033

5.  Somatization in primary care. Prevalence, health care utilization, and general practitioner recognition.

Authors:  P Fink; L Sørensen; M Engberg; M Holm; P Munk-Jørgensen
Journal:  Psychosomatics       Date:  1999 Jul-Aug       Impact factor: 2.386

6.  Alexithymic characteristics and patient-therapist interaction: a video analysis of facial affect display.

Authors:  Marcus Rasting; Burkhard Brosig; Manfred E Beutel
Journal:  Psychopathology       Date:  2005-05-16       Impact factor: 1.944

Review 7.  The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10.

Authors:  D V Sheehan; Y Lecrubier; K H Sheehan; P Amorim; J Janavs; E Weiller; T Hergueta; R Baker; G C Dunbar
Journal:  J Clin Psychiatry       Date:  1998       Impact factor: 4.384

8.  Alexithymia and life satisfaction in primary healthcare patients.

Authors:  Aino K Mattila; Outi Poutanen; Anna-Maija Koivisto; Raimo K R Salokangas; Matti Joukamaa
Journal:  Psychosomatics       Date:  2007 Nov-Dec       Impact factor: 2.386

9.  Alexithymia and somatization in general population.

Authors:  Aino K Mattila; Erkki Kronholm; Antti Jula; Jouko K Salminen; Anna-Maija Koivisto; Riitta-Liisa Mielonen; Matti Joukamaa
Journal:  Psychosom Med       Date:  2008-07-02       Impact factor: 4.312

10.  Quality of life and dyadic adjustment in oral cancer patients and their female partners.

Authors:  J Jenewein; R A Zwahlen; D Zwahlen; N Drabe; H Moergeli; S Büchi
Journal:  Eur J Cancer Care (Engl)       Date:  2008-03       Impact factor: 2.520

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.